Affected Systems |
|
|
|
|
|
|
|
|
|
|
|
|
cellular
|
|
|
√
|
|
|
|
√
|
|
√
|
√
|
|
abnormal intestinal goblet cell morphology
|
|
|
|
|
|
|
√
|
|
|
√
|
|
abnormal autophagy
|
|
|
|
|
|
|
|
|
√
|
|
|
increased hepatocyte apoptosis
|
|
|
√
|
|
|
|
|
|
|
|
|
increased small intestinal crypt cell apoptosis
|
|
|
|
|
|
|
|
|
|
√
|
|
digestive/alimentary system
|
|
|
|
√
|
√
|
|
√
|
√
|
√
|
√
|
√
|
abnormal intestinal goblet cell morphology
|
|
|
|
|
|
|
√
|
|
|
√
|
|
abnormal intestine development
|
|
|
|
|
|
|
|
|
|
√
|
|
abnormal intestinal epithelium morphology
|
|
|
|
|
|
|
|
|
|
√
|
|
abnormal small intestine crypts of Lieberkuhn morphology
|
|
|
|
|
|
|
|
|
|
√
|
|
abnormal Paneth cell morphology
|
|
|
|
|
|
|
√
|
|
|
|
|
abnormal colon morphology
|
|
|
|
|
|
|
|
|
|
√
|
|
rectal prolapse
|
|
|
|
|
|
|
|
|
√
|
|
|
decreased intestinal adenoma incidence
|
|
|
|
|
|
|
√
|
|
|
|
|
increased intestinal adenocarcinoma incidence
|
|
|
|
|
√
|
|
|
|
|
|
√
|
increased intestinal adenoma incidence
|
|
|
|
√
|
|
|
|
√
|
√
|
|
|
increased colon adenoma incidence
|
|
|
|
|
|
|
|
√
|
√
|
|
|
intestine polyps
|
|
|
|
|
|
|
|
|
√
|
|
|
abnormal gut flora balance
|
|
|
|
|
|
|
√
|
|
√
|
|
|
abnormal intestine physiology
|
|
|
|
|
|
|
√
|
|
|
|
|
increased small intestinal crypt cell apoptosis
|
|
|
|
|
|
|
|
|
|
√
|
|
endocrine/exocrine glands
|
|
|
|
|
|
|
√
|
|
|
√
|
|
abnormal small intestine crypts of Lieberkuhn morphology
|
|
|
|
|
|
|
|
|
|
√
|
|
abnormal Paneth cell morphology
|
|
|
|
|
|
|
√
|
|
|
|
|
growth/size/body
|
√
|
√
|
|
|
|
|
|
|
√
|
|
|
cachexia
|
|
|
|
|
|
|
|
|
√
|
|
|
enlarged liver
|
|
√
|
|
|
|
|
|
|
|
|
|
liver hyperplasia
|
√
|
|
|
|
|
|
|
|
|
|
|
hematopoietic system
|
|
√
|
√
|
|
|
|
√
|
|
|
|
|
increased CD103-positive CD11b-low dendritic cell number
|
|
|
|
|
|
|
√
|
|
|
|
|
increased CD8-positive, alpha-beta T cell number
|
|
|
|
|
|
|
√
|
|
|
|
|
decreased NK T cell number
|
|
√
|
|
|
|
|
|
|
|
|
|
increased NK T cell number
|
|
|
√
|
|
|
|
|
|
|
|
|
increased regulatory T cell number
|
|
|
|
|
|
|
√
|
|
|
|
|
abnormal neutrophil physiology
|
|
|
√
|
|
|
|
|
|
|
|
|
abnormal NK T cell physiology
|
|
√
|
√
|
|
|
|
|
|
|
|
|
homeostasis/metabolism
|
|
|
√
|
|
|
|
|
|
√
|
|
|
abnormal autophagy
|
|
|
|
|
|
|
|
|
√
|
|
|
abnormal circulating enzyme level
|
|
|
√
|
|
|
|
|
|
|
|
|
abnormal chemokine level
|
|
|
√
|
|
|
|
|
|
|
|
|
immune system
|
|
√
|
√
|
|
|
|
√
|
|
|
|
|
increased CD103-positive CD11b-low dendritic cell number
|
|
|
|
|
|
|
√
|
|
|
|
|
increased CD8-positive, alpha-beta T cell number
|
|
|
|
|
|
|
√
|
|
|
|
|
decreased NK T cell number
|
|
√
|
|
|
|
|
|
|
|
|
|
increased NK T cell number
|
|
|
√
|
|
|
|
|
|
|
|
|
increased regulatory T cell number
|
|
|
|
|
|
|
√
|
|
|
|
|
abnormal immune system physiology
|
|
|
|
|
|
|
√
|
|
|
|
|
abnormal neutrophil physiology
|
|
|
√
|
|
|
|
|
|
|
|
|
abnormal NK T cell physiology
|
|
√
|
√
|
|
|
|
|
|
|
|
|
abnormal chemokine level
|
|
|
√
|
|
|
|
|
|
|
|
|
decreased interferon-gamma secretion
|
|
|
√
|
|
|
|
|
|
|
|
|
increased interferon-gamma secretion
|
|
√
|
|
|
|
|
|
|
|
|
|
increased interleukin-1 beta secretion
|
|
|
|
|
|
|
√
|
|
|
|
|
increased interleukin-10 secretion
|
|
|
|
|
|
|
√
|
|
|
|
|
increased interleukin-4 secretion
|
|
√
|
√
|
|
|
|
|
|
|
|
|
liver inflammation
|
|
√
|
√
|
|
|
|
|
|
|
|
|
liver/biliary system
|
√
|
√
|
√
|
|
|
|
|
|
|
|
|
increased hepatocyte apoptosis
|
|
|
√
|
|
|
|
|
|
|
|
|
liver inflammation
|
|
√
|
√
|
|
|
|
|
|
|
|
|
abnormal liver morphology
|
|
√
|
√
|
|
|
|
|
|
|
|
|
enlarged liver
|
|
√
|
|
|
|
|
|
|
|
|
|
liver hyperplasia
|
√
|
|
|
|
|
|
|
|
|
|
|
hepatic necrosis
|
|
|
√
|
|
|
|
|
|
|
|
|
increased hepatocellular carcinoma incidence
|
√
|
|
|
|
|
|
|
|
|
|
|
mortality/aging
|
√
|
|
√
|
|
√
|
|
|
|
√
|
√
|
|
premature death
|
√
|
|
√
|
|
√
|
|
|
|
|
√
|
|
decreased tumor-free survival time
|
|
|
|
|
|
|
|
|
√
|
|
|
neoplasm
|
√
|
|
|
√
|
√
|
N
|
√
|
√
|
√
|
|
√
|
neoplasm
|
|
|
|
|
|
N
|
|
|
|
|
|
decreased intestinal adenoma incidence
|
|
|
|
|
|
|
√
|
|
|
|
|
increased intestinal adenocarcinoma incidence
|
|
|
|
|
√
|
|
|
|
|
|
√
|
increased intestinal adenoma incidence
|
|
|
|
√
|
|
|
|
√
|
√
|
|
|
increased colon adenoma incidence
|
|
|
|
|
|
|
|
√
|
√
|
|
|
increased hepatocellular carcinoma incidence
|
√
|
|
|
|
|
|
|
|
|
|
|